7 from Group 1 were not allowed to continue based on our protocol, while 5 from Group 2 were released due to a lack of further improvement. The mean gain in acuity after 8, 16 or 24 weeks was 0.20±0.24, 0.24±0.11 or 0.41±0.16 LogMAR respectively (see Supp. Lower age has been associated with higher probability of a successful treatment, possibly preventing the applicability of a treatment in adults: compliance (e.g. to patching) reduces with increasing age (Wallace et al. 2013 , Stewart et al., 2005 , Scheiman et al., 2005 and so does cortical plasticity (Lewis et al., 2005) . Using regression analysis (least-squares fitting)
we found that the age of participants did not differentially influence the change in acuity in the AE (R 2 = 0.001, p(F=0.03) =0.87; see Supp. Fig. 1D ). Accordingly, there was no dependence of age for children in Group 1 (mean age 9.46±1.93 yrs) or Group 2 (mean age 5.12±1.97 yrs), on the final gain in acuity in the AE (two-sample t-test: p=0.86). Within Group 1, we did however find an effect of age on stereoacuity measurements (Wilcoxon-paired, p=0.02 at α=0.05), though this was not measureable in Group 2. Finally, we considered the possibility that suppression changed with age by taking the individual suppression index averaged over the daily measures, for the duration of BBV treatment. Here we found no significant dependence of age on suppression (R 2 = 0.14, p (F=3.21) =0.09). Relations between the type of amblyopia and the improvement in VA (none were significant). The dashed lines (in A and B) show the mean test-retest reliability for acuity tests in children. Error bars show one standard error of uncertainty. C: Severity of amblyopia (initial VA in the AE) showed moderate influence on acuity gain in the AE, though this was not significant (R 2 = 0.134, p=0.09). D: Age (yrs) was not significantly correlated (R 2 = 0.001, p=0.87) with acuity gain in the AE.
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